Maravai Lifesciences Intrinsic Value Calculator – Analyst Forecasts Turn Negative for Maravai LifeSciences Holdings,
November 22, 2023
🌧️Trending News
Maravai ($NASDAQ:MRVI) LifeSciences Holdings, Inc. is a biotechnology company that specializes in providing services and products for molecular biology research, diagnostics, and therapeutics. Recently, analyst forecasts for the company have turned negative. Analysts have become more pessimistic about the prospects of Maravai LifeSciences Holdings, Inc., citing a range of potential issues. Many are concerned about the lack of profitability and sustainable revenues for the company. They worry that the company may not be able to generate enough income to cover its expenses. Furthermore, analysts are also raising questions about the company’s long-term growth prospects, citing potential challenges posed by the competitive landscape. In light of these concerns, analysts are recommending investors wait and see how the company performs before investing. It remains to be seen whether Maravai LifeSciences will be able to overcome its current challenges and turn its fortunes around. If the company is able to do so, investors could be in for a lucrative return.
However, until then, analysts are advising caution.
Market Price
On Friday, MARAVAI LIFESCIENCES Holdings, Inc. saw its stock price take a sharp turn for the worse, opening at $5.1 and closing at $5.0, down 1.8% from the previous closing price of $5.1. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 419.52 | 24.56 | 7.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…
| Operations | Investing | Financing |
| 217.77 | -127.93 | -127.68 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.27k | 1.38k | 3.94 |
Key Ratios Snapshot
Some of the financial key ratios for Maravai Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.7% | 6.1% | 23.4% |
| FCF Margin | ROE | ROA |
| 38.8% | 11.8% | 2.7% |
Analysis – Maravai Lifesciences Intrinsic Value Calculator
At GoodWhale, we have analyzed MARAVAI LIFESCIENCES‘ financials through our proprietary Valuation Line. After careful examination, we are confident that the intrinsic value of MARAVAI LIFESCIENCES share is around $16.1. On the market, however, the MARAVAI LIFESCIENCES stock is currently being traded at only $5.0 – an incredible 69.0% lower than its true worth. This presents an amazing opportunity for any investor looking for a profitable investment opportunity! More…
Peers
The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.
– Takara Bio Inc ($TSE:4974)
Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.
– Forward Pharma A/S ($NASDAQ:FWP)
Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:
Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.
– Obio Technology (shanghai) Corp Ltd ($SHSE:688238)
Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.
Summary
Investors should take note of Maravai LifeSciences Holdings, Inc. as analyst forecasts have become more bearish recently. The company’s stock price has declined, sinking significantly in recent weeks. Analysts are not confident in the company’s prospects, lowering their outlook for future returns. In addition to the waning sentiment, Maravai LifeSciences has seen its market share and revenue decrease in recent quarters.
It is important for investors to keep a close eye on the company’s financials and news developments while taking note of analyst forecasts. Long-term investors should also consider the company’s fundamentals and consider any potential risks before investing.
Related Posts
Recent Posts
